Skip to main content

(Test) Meet Korean Pharma companies in Basel

Korea has emerged as a strong player in the global pharmaceutical landscape. The Korean pharmaceutical industry not only holds a huge R&D pipeline, but also possesses a strong portfolio of stringent regulatory authority (SRA) approvals – an interesting market for European companies.

Could Korea be the next market for your pharmaceutical product? Are you curious to learn why they are interested in Basel and what are their goals here?

Join us for an exceptional opportunity of networking with three Korean pharmaceutical companies, all among the top ten in their country: Ildong Pharmaceutical, Daewoong Pharmaceutical and Yuhan Corporation. To save you a trip to Seoul, we have invited the companies to Basel.

Our three guests will introduce their companies, their partnering strategies, and areas of interest. Connect with our speakers and find out how you can collaborate with them!
This event is empowered by Innosuisse.



Door Opening


Welcome by Basel Area Business & Innovation



  • Hyunwoo Lee, Executive Director, International Affairs Department,


Daewoong Pharmaceutical


Ildong Pharmaceutical


Yuhan Corporation

  • Han Kim, Regional Representative for Europe,


Networking Apero

For further information

To be added below the agenda on the website, maybe with the logo – copied in the bottom of the page - (not included in the invitation email!!):
  • - Daewoong Pharmaceutical: Daewoong established in 1945 has the largest prescription drug sales in the South Korean market and commercializes 10 blockbuster products. Their core competencies are drug development and expanded regional and global collaborations with international partners. They’ve invested approximately 15% of their sales in R&D. Especially, two NCEs, a novel P-CAB class for the treatment of GERD and Gastritis, “Fexuprazan” and, “Enavogliflozin” a novel SGLT2 inhibitor for T2DM were approved in Korea last year. Also, of the 5 different R&D fields within DW, iN Therapeutics(iNT), a research-based biotech, focusing on innovation to develop first-in-class drugs of ion channels for neurological disorders was the most promising one, which resulted in spinning off from DW and establishing stand-a-lone cooperation in 2020. With success in preclinical data, a phase 1 SAD study of iN1011-N17 expected to be a new analgesic is being conducted in Australia.
  • - Ildong Pharmaceutical: A fully integrated pharmaceutical company founded in 1941. In the past few years, they have maintained an industry-leading R&D investment level (15-20% of sales) which has resulted in over 25 innovative R&D assets including five clinical programs. The pipelines cover multiple therapeutic areas including metabolic, GI, ophthalmology, CNS, and oncology.
  • - Yuhan Corporation: This top-selling pharmaceutical company was founded in 1926. Their sales revenue is $1.5B. In the past several years, Yuhan has signed licensing deals with Gilead, Janssen, Boehringer Ingelheim and other global pharmaceutical companies with a combined deal size exceeding $3.5B. The company is looking for collaboration opportunities to jointly develop advanced life science ecosystems with other global pharmaceutical players around the world.